Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1142]

ASCO GU 2023: Latest updates in mRCC

Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor...

ASCO GU 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor Grünwald and Prof Toni Choueiri )

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in...

Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC ( Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Nivolumab and salvage nivolumab plus ipilimumab for aRCC

Prof Michael Atkins - Georgetown Lombardi Comprehensive Cancer Center...

Nivolumab and salvage nivolumab plus ipilimumab for aRCC ( Prof Michael Atkins - Georgetown Lombardi Comprehensive Cancer Center, Georgetown, USA )

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Anti-PSMA antibody radiolabeled with 177Lu improves MFS in high-risk nmCRPC

Prof Scott Tagawa - Weill Cornell Medicine, New York City, USA

Anti-PSMA antibody radiolabeled with 177Lu improves MFS in high-risk nmCRPC ( Prof Scott Tagawa - Weill Cornell Medicine, New York City, USA )

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive...

Prof Siamak Daneshmand - University of Southern California, Los Angeles, USA

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive bladder cancer with FGFR alterations ( Prof Siamak Daneshmand - University of Southern California, Los Angeles, USA )

Cell-free utDNA may predict transurethral resection of bladder tumour pathology...

Dr Kyle Rose - Moffitt Cancer Center, Florida, USA

Cell-free utDNA may predict transurethral resection of bladder tumour pathology in non–muscle invasive bladder cancer ( Dr Kyle Rose - Moffitt Cancer Center, Florida, USA )

IMvigor130 study: Final OS analysis of atezo + plt/gem vs placebo + plt/gem...

Prof Aristotelis Bamias - University of Athens, Athens, Greece

IMvigor130 study: Final OS analysis of atezo + plt/gem vs placebo + plt/gem used to treat mUC ( Prof Aristotelis Bamias - University of Athens, Athens, Greece )

Hypofractionated high dose intensity modulated radiotherapy non-inferior for...

Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK

$Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer ( Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK )$

JAVELIN Bladder 100: Avelumab maintenance indicated as a standard of care for...

Dr Srikala Sridhar - Princess Margaret Cancer Centre, Ontario, Canada

JAVELIN Bladder 100: Avelumab maintenance indicated as a standard of care for advanced urothelial carcinoma ( Dr Srikala Sridhar - Princess Margaret Cancer Centre, Ontario, Canada )

More from ecancer